Author (reference) County | Activity of disease | Test Method | Age (female %) | CD N/ LM | Age (female %) | UC N/ LM | Age (female %) | Control N / LM | NOS Score |
---|---|---|---|---|---|---|---|---|---|
Gupta [33] India | I | BT | 34.7 (26)a | 27 / 10a | 36.2 | 18 / 10a | 36.2 (26)a | 45 / 12 | 7 |
Eadala [24] Wales UK | Ic | BT Gen | 19–86 (38) | 70d / 2b | 20–81 (44) | 95 / 11b | 21–56 (15) | 30 / 0 | 8 |
Barrett [25] Australia | Ic | BT | 40 (56) | 92d / 39 | 40 (44) | 56 / 22 | 34 (20) | 71 / 13 | 9 |
Banos Madrid [34] Spain | nd | BT | nd | 18 / 3 | nd | 24 / 4 | nd | 25 / 5 | 7 |
Ginard [35] Spain | nd | BT Quest | nd | nd | 40 (32) | 52 / 13 | 41 (20) | 34 / 11 | 7 |
Von Turpitz [26] Germany | 24A 25Ic | BT Bx | 39.9 (30) | 49 / 16 | nd | nd | 43.1 (11) | 24 / 5 | 6 |
Mishkin [15] Canadaf | Ic | BT | 36.9 (62) | 121d / 70 | 37 (71) | 139 / 65 | nd nd | 158 / 46 | 8 |
Bernstein [27] Canadaf | 18A 11I | BT Quest | nd | nd | 39 (13) | 29 / 13 | 41 (4) | 14 / 5 | 8 |
Kochlar [36] India | 22A 38I | BT | nd | nd | 36.7 (35) | 60 / 25 | 36.4 (7) | 20 / 8 | 7 |
Ogata [38] Japan | nd | BT LTT | nd | 32/29BT32/30LTT | nd | nd | nd | 51/26BT51/37LTT | nd |
Park [28] Scotland | 21A 41I | Bx | 40 (38) | 62d | nd | nd | 40 (9) | 13 | 5 |
Lobely [29] England | nd | USR | 42 nd | 16 | 42 (nd) | 6 | 28.5 (13) | 40 | 6 |
Pironi [37] Italy | Ic | BT | 33 (23) | 37 / 18 | nd | nd | 35 (36) | 67 / 11 | 7 |
Kirschner [30] United Statesf | 37Ag 33I of IBD | BT | 13.5 (nd) | 50 / 17 | 13.5 (nd) | 20 / 5 | nd (nd) | 42 | 7 |
Pena [23] England | 37A 35I | Bx | nd | nd | nd | 72 / 9 | nd | 21 / 2 | 6 |
Tandon [31] United Statesf | nd | LTT | nd | nd | nd | 70e [51/12] [19/16] | nd | 94e [53/11] [41/29] | 7 |
Chalfin [32] United States | nd | LTT | 40.8 (2) | 5 / 3 | 42.8 (5) | 9 / 4 | 44.3 (7) | 12 | 5 |